Cargando…

HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping

SIMPLE SUMMARY: Classical clinical research has been developed according to immunohistochemical breast cancer subtypes, instead of designing trials specifically for each molecular subtype. Efforts in de-escalating treatment should focus on identifying a subgroup of HER2 oncogene addicted tumours tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Bueno Muiño, Coralia, Martín, Miguel, del Monte-Millán, María, García-Saénz, José Ángel, López-Tarruella, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833556/
https://www.ncbi.nlm.nih.gov/pubmed/35158778
http://dx.doi.org/10.3390/cancers14030512
_version_ 1784648972870090752
author Bueno Muiño, Coralia
Martín, Miguel
del Monte-Millán, María
García-Saénz, José Ángel
López-Tarruella, Sara
author_facet Bueno Muiño, Coralia
Martín, Miguel
del Monte-Millán, María
García-Saénz, José Ángel
López-Tarruella, Sara
author_sort Bueno Muiño, Coralia
collection PubMed
description SIMPLE SUMMARY: Classical clinical research has been developed according to immunohistochemical breast cancer subtypes, instead of designing trials specifically for each molecular subtype. Efforts in de-escalating treatment should focus on identifying a subgroup of HER2 oncogene addicted tumours that are especially sensitive to anti-HER2 therapies and, thus, spare unnecessary treatments. A prognostic assay that integrates molecular tumour features with clinical and pathologic variables and accurately defines a group of HER2 addicted tumours remains the best candidate among these strategies. ABSTRACT: Long-term outcomes in breast cancer patients differ based on the molecular subtype, with HER2-E being the most aggressive one. Advances in clinical practice have dramatically shifted HER2+ breast cancer prognosis. Risk adapted strategies to individualize therapies are necessary. De-escalation approaches have been encouraged based on the risks of clinical-pathological factors. Molecular gene subtyping could further accurately define HER2 addicted tumours that are sensitive to anti-HER2 therapies, thus sparing unnecessary treatments. The transition from immunochemistry to molecular profiling in HER2+ breast cancer is discussed.
format Online
Article
Text
id pubmed-8833556
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88335562022-02-12 HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping Bueno Muiño, Coralia Martín, Miguel del Monte-Millán, María García-Saénz, José Ángel López-Tarruella, Sara Cancers (Basel) Review SIMPLE SUMMARY: Classical clinical research has been developed according to immunohistochemical breast cancer subtypes, instead of designing trials specifically for each molecular subtype. Efforts in de-escalating treatment should focus on identifying a subgroup of HER2 oncogene addicted tumours that are especially sensitive to anti-HER2 therapies and, thus, spare unnecessary treatments. A prognostic assay that integrates molecular tumour features with clinical and pathologic variables and accurately defines a group of HER2 addicted tumours remains the best candidate among these strategies. ABSTRACT: Long-term outcomes in breast cancer patients differ based on the molecular subtype, with HER2-E being the most aggressive one. Advances in clinical practice have dramatically shifted HER2+ breast cancer prognosis. Risk adapted strategies to individualize therapies are necessary. De-escalation approaches have been encouraged based on the risks of clinical-pathological factors. Molecular gene subtyping could further accurately define HER2 addicted tumours that are sensitive to anti-HER2 therapies, thus sparing unnecessary treatments. The transition from immunochemistry to molecular profiling in HER2+ breast cancer is discussed. MDPI 2022-01-20 /pmc/articles/PMC8833556/ /pubmed/35158778 http://dx.doi.org/10.3390/cancers14030512 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bueno Muiño, Coralia
Martín, Miguel
del Monte-Millán, María
García-Saénz, José Ángel
López-Tarruella, Sara
HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping
title HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping
title_full HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping
title_fullStr HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping
title_full_unstemmed HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping
title_short HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping
title_sort her2+ breast cancer escalation and de-escalation trial design: potential role of intrinsic subtyping
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833556/
https://www.ncbi.nlm.nih.gov/pubmed/35158778
http://dx.doi.org/10.3390/cancers14030512
work_keys_str_mv AT buenomuinocoralia her2breastcancerescalationanddeescalationtrialdesignpotentialroleofintrinsicsubtyping
AT martinmiguel her2breastcancerescalationanddeescalationtrialdesignpotentialroleofintrinsicsubtyping
AT delmontemillanmaria her2breastcancerescalationanddeescalationtrialdesignpotentialroleofintrinsicsubtyping
AT garciasaenzjoseangel her2breastcancerescalationanddeescalationtrialdesignpotentialroleofintrinsicsubtyping
AT lopeztarruellasara her2breastcancerescalationanddeescalationtrialdesignpotentialroleofintrinsicsubtyping